Engineering spleen-tropic lipid nanoparticles for immune-cell delivery, RNA therapeutics, and organ-selective formulation discovery.
Spleen-targeted lipid nanoparticle (LNP) development is an advanced formulation strategy designed to shift nanocarrier accumulation and functional cargo expression toward splenic immune compartments rather than default hepatic uptake. For teams developing RNA medicines, immune-modulating payloads, antigen expression systems, and gene-editing cargos, the spleen offers a biologically meaningful destination because it contains dense populations of dendritic cells, macrophages, B cells, T cells, and other antigen-presenting cells involved in immune surveillance and response shaping. However, achieving reproducible spleen tropism requires more than simply changing particle size or adding a ligand. It depends on a coordinated optimization of ionizable lipid chemistry, helper lipid composition, PEG-lipid architecture, surface charge, protein corona behavior, cargo format, and process parameters.
BOC Sciences provides targeted LNP development services for research teams seeking spleen-biased delivery profiles, immune-cell transfection, and rational formulation screening. Our workflow integrates formulation design, microfluidic preparation, physicochemical characterization, in vitro cell assays, ex vivo splenocyte profiling, and in vivo biodistribution analysis to help clients identify LNP candidates with balanced encapsulation, stability, organ selectivity, and functional expression.
Spleen-targeted LNP development should not stop at total organ accumulation. The spleen contains functionally distinct microenvironments, including the red pulp, marginal zone, white pulp, B-cell follicles, T-cell-rich periarteriolar lymphoid sheath, and antigen-presenting cell interfaces. BOC Sciences develops spleen-oriented LNPs by matching formulation attributes, surface engineering strategies, lipid chemistry, and biological readouts to the intended splenic substructure and immune-cell population.
The marginal zone is a key interface for blood-borne particle capture, antigen recognition, and communication between innate and adaptive immune cells. LNPs designed for this region are suitable for antigen-encoding RNA, immune-modulating siRNA, reporter mRNA, and payloads intended to interact with splenic macrophages, dendritic cells, or marginal zone B-cell-associated pathways.
The red pulp is involved in blood filtration and contains abundant macrophage populations that efficiently interact with circulating particles. Red pulp-oriented LNPs are useful for macrophage biology studies, phagocyte-targeted RNA delivery, inflammatory pathway modulation, and biodistribution models requiring strong splenic phagocyte engagement.
The white pulp is enriched with lymphoid cells and supports adaptive immune response initiation. LNPs designed for white pulp-associated delivery are suitable for antigen expression, immune education models, mRNA-based protein production, and payloads requiring interaction with antigen-presenting cells and lymphocyte-rich regions.
B-cell follicles are relevant for projects exploring B-cell interaction, antigen display, antibody-response mechanisms, and follicular immune-cell communication. This development route is suitable for antigen-associated LNPs, mRNA expression systems, and exploratory B-cell-targeted delivery studies.
The periarteriolar lymphoid sheath (PALS) is a T-cell-rich region associated with immune activation and antigen presentation. Direct LNP delivery to T-cell zones is challenging, so development often focuses on dendritic cell-mediated antigen presentation, local immune-cell interaction, and downstream T-cell response models.
A spleen-enriched LNP candidate may still fail if it accumulates in the wrong compartment or does not release cargo in the intended cell type. BOC Sciences combines formulation screening with organ-level, cell-level, and function-level evaluation to select candidates with meaningful spleen-oriented delivery performance.
Spleen-selective LNP development requires deliberate control of particle properties, surface interactions, lipid chemistry, and biological validation models. Rather than relying on a single targeting factor, BOC Sciences applies an integrated strategy to reduce liver-favored uptake while improving splenic access, immune-cell interaction, and functional cargo delivery.
Move beyond liver-biased default delivery. Develop, compare, and validate LNP candidates for splenic immune-cell delivery with integrated formulation and biodistribution support.
BOC Sciences supports the development of spleen-targeted LNPs in multiple formulation formats according to the intended administration route, cargo properties, immune-cell target, and evaluation model. Each dosage form is designed with attention to particle stability, cargo protection, splenic exposure, and compatibility with downstream biodistribution and functional assays.
| Dosage Form | Administration Route | Suitable Payloads and Development Focus |
|---|---|---|
| Aqueous LNP Dispersion | Intravenous injection | Suitable for mRNA, siRNA, circRNA, pDNA, CRISPR RNPs, and peptide-associated cargos requiring systemic spleen exposure. Development focuses on particle size control, serum stability, spleen/liver distribution balance, and functional expression in splenic immune-cell subsets. |
| Lyophilized LNP Powder | Reconstitution before injection | Applicable to RNA-loaded LNPs, protein-associated LNPs, and temperature-sensitive exploratory formulations. We optimize cryoprotectant selection, reconstitution behavior, particle-size recovery, encapsulation retention, and post-reconstitution activity. |
| Concentrated LNP Suspension | Intravenous, subcutaneous, or intradermal administration depending on project design | Suitable for high-dose RNA, antigen-encoding cargo, immune-modulating siRNA, and multi-component LNP systems. Development emphasizes concentration tolerance, viscosity control, aggregation prevention, and maintenance of spleen-oriented biodistribution after dilution or administration. |
| Ligand-Modified LNP Formulation | Intravenous or local immune-tissue-adjacent administration | Designed for cargos requiring enhanced recognition by splenic macrophages, dendritic cells, B-cell-associated compartments, or antigen-presenting cell populations. Suitable ligands may include mannose, galactose, CD169-related binders, or CD21/CD35-associated targeting motifs. |
| Hydrogel-Associated LNP Depot | Subcutaneous or intradermal administration | Suitable for antigen-encoding mRNA, immune-modulating RNA, peptide-associated payloads, or protein cargos requiring sustained local release and secondary immune-tissue exposure. Development focuses on LNP-gel compatibility, release kinetics, particle integrity, and immune-cell interaction. |
| Ex Vivo Cell-Contacting LNP Format | Ex vivo splenocyte or immune-cell treatment | Used for formulation screening, mechanistic uptake studies, and comparison of cargo activity in isolated immune-cell populations. Suitable for reporter mRNA, siRNA, fluorescent RNA, labeled protein, and CRISPR RNP cargos before advancing to organ-level biodistribution evaluation. |
Spleen-targeted LNP projects often fail because high nanoparticle uptake does not automatically translate into functional cargo delivery. We address the formulation and assay challenges that determine whether a candidate is truly spleen-selective and biologically active.
✔ Strong Liver Bias
Conventional LNPs frequently show dominant liver accumulation after systemic delivery. We redesign lipid composition, PEG-lipid structure, and particle attributes to improve spleen/liver signal balance.
✔ Uptake Without Expression
Nanoparticles may enter splenic cells but fail to release cargo into the cytosol. We evaluate endosomal escape, ionizable lipid behavior, and intracellular release using functional reporter assays.
✔ Poor APC Selectivity
Total spleen signal can mask low delivery to dendritic cells or macrophages. We apply cell-subset profiling to identify which immune populations actually receive and express the cargo.
✔ Cargo-Dependent Instability
mRNA, siRNA, pDNA, circRNA, proteins, and RNPs require different encapsulation environments. We optimize buffer, N/P ratio, lipid ratio, and mixing conditions for each cargo type.
✔ Misleading Biodistribution Data
Fluorescent lipid labels, cargo labels, and expression reporters can produce different distribution patterns. We combine orthogonal assays to separate particle localization from functional cargo delivery.
✔ Scale-Sensitive Performance Shift
A promising small-batch LNP may change size, encapsulation, or expression after process adjustment. We connect formulation screening with controlled process optimization to preserve candidate behavior.
We review your cargo type, target splenic cell population, administration plan, current formulation data, and desired spleen/liver distribution profile to define a practical development strategy.
A focused LNP library is prepared using controlled lipid composition, PEG-lipid ratio, aqueous phase condition, and microfluidic mixing parameters.
Candidate LNPs are assessed for particle size, PDI, zeta potential, encapsulation, morphology, serum stability, in vitro activity, and ex vivo immune-cell interaction.
We compare organ-level and cell-subset-level data to identify lead spleen-tropic candidates, then provide formulation recommendations and next-step optimization logic.
Challenge: A research team developing an antigen-encoding mRNA LNP observed strong total spleen fluorescence but weak functional expression in dendritic cells. Their original formulation had a particle size of approximately 95 nm, high mRNA encapsulation, and acceptable colloidal stability, yet flow cytometry showed that most detectable signal came from macrophage-rich fractions rather than CD11c+ antigen-presenting cells.
Diagnosis: BOC Sciences compared fluorescent lipid tracking, cargo-associated signal, and reporter protein expression. The results suggested that particle uptake and mRNA translation were uncoupled. The initial LNP was efficiently captured by splenic phagocytes but showed limited endosomal escape in the target APC subset.
Solution: We constructed a 24-formulation screening matrix using three ionizable lipid ratios, two helper lipid compositions, two PEG-lipid levels, and two particle-size windows generated via controlled microfluidic mixing. After initial characterization, six candidates were advanced to splenocyte profiling. The best-performing candidate showed a slightly smaller size distribution, lower PEG-lipid shielding, and improved reporter expression in CD11c+ cells without a proportional increase in liver expression.
Result: The optimized formulation increased functional reporter expression in splenic APC-enriched populations by approximately 4.6-fold compared with the starting formulation, while preserving mRNA encapsulation above the project-defined threshold and maintaining a narrow particle-size distribution.
Challenge: A client working with a macrophage-modulating siRNA LNP needed to improve spleen selectivity. The initial formulation produced measurable gene silencing in splenic macrophages but also generated a strong liver-associated signal, making it difficult to interpret spleen-specific activity.
Diagnosis: Comparative biodistribution analysis indicated that the formulation's lipid composition and surface behavior favored hepatic uptake. Zeta potential measurements, serum stability testing, and post-incubation size tracking suggested that the original PEG-lipid ratio was insufficient to control protein adsorption and aggregation under serum-containing conditions.
Solution: We redesigned the formulation around a narrower size target and evaluated PEG-lipid chain behavior, helper lipid proportion, and ionizable lipid-to-siRNA ratio. Candidate screening included encapsulation analysis, serum incubation, macrophage uptake, and organ distribution readouts. One formulation with adjusted PEG-lipid architecture and modified helper lipid balance produced a higher spleen/liver signal ratio while preserving siRNA activity in F4/80+ splenic macrophages.
Result: The selected candidate reduced liver-dominant signal and improved spleen-associated functional knockdown compared with the original formulation. The client received a formulation rationale, comparative data table, and recommended next-step design space for macrophage-focused LNP refinement.
Organ-Tropism Design LogicWe do not treat spleen targeting as a single-variable adjustment. Our design strategy considers lipid chemistry, surface behavior, process conditions, cargo type, and immune-cell biology together.
Integrated LNP OptimizationOur services connect LNP ionizable lipid optimization, LNP PEG-lipid optimization, encapsulation tuning, and biological evaluation into one coordinated workflow.
Microfluidic Process ControlWe apply microfluidic LNP production methods to control size, PDI, mixing reproducibility, and formulation comparability across screening rounds.
Comprehensive CharacterizationCandidate LNPs can be evaluated through lipid nanoparticle characterization, encapsulation analysis, stability tracking, morphology assessment, and orthogonal biodistribution readouts.
Function-Focused ScreeningWe combine nanoparticle cellular and in vivo evaluation with cell-subset profiling to determine whether spleen accumulation leads to useful biological activity.
Spleen-targeted LNP development is challenging because the formulation must balance circulation behavior, organ distribution, immune-cell interaction, cargo protection, and intracellular release. Many conventional LNP systems naturally show strong liver accumulation, so shifting delivery toward the spleen requires careful adjustment of lipid composition, particle size, PEG-lipid structure, surface properties, and cargo-to-lipid ratio. The spleen also contains multiple immune cell populations, including macrophages, dendritic cells, B cells, and T cells, each of which may respond differently to LNP physicochemical features. For this reason, successful development requires more than a single biodistribution readout; it needs formulation screening, physicochemical characterization, cell-level uptake analysis, and functional expression or silencing assessment.
Several formulation parameters can influence spleen delivery, including ionizable lipid structure, helper lipid selection, cholesterol ratio, PEG-lipid chain length, PEG-lipid molar percentage, N/P ratio, particle size, polydispersity, surface charge, and cargo type. For nucleic acid payloads such as mRNA, siRNA, or circular RNA, the internal packing state and surface presentation of the LNP can affect both stability and biological performance. A formulation that works well for one cargo may not be optimal for another. BOC Sciences can support clients by designing comparative formulation matrices, evaluating key size and charge profiles, assessing encapsulation behavior, and identifying candidate LNP systems that show improved spleen-oriented delivery potential while maintaining suitable colloidal and cargo-protective properties.
Spleen-targeted LNP systems are valuable for research programs focused on immune-cell delivery, antigen expression, gene silencing, immunomodulatory RNA delivery, and evaluation of novel RNA cargos in lymphoid tissues. Because the spleen is rich in antigen-presenting cells and other immune cell populations, it is an important tissue for studying how LNP structure influences immune-cell uptake and downstream biological activity. These systems may be used to explore mRNA expression in dendritic cells, siRNA-mediated knockdown in macrophage-related models, or delivery behavior of engineered RNA constructs. For project teams, the key question is not only whether the LNP reaches the spleen, but whether the intended cell population receives the cargo and produces a measurable functional response.
Spleen-targeting performance should be evaluated using a layered analytical strategy rather than relying on total organ fluorescence or a single expression signal. Bulk tissue readouts can be influenced by residual blood signal, dye detachment, liver-spleen overlap, or differences between particle accumulation and cargo release. A stronger evaluation framework includes LNP size, PDI, zeta potential, encapsulation analysis, serum stability, tissue distribution, spleen cell subset uptake, and functional cargo activity. For RNA-loaded LNPs, expression or knockdown data should ideally be interpreted together with cell-type information. BOC Sciences helps clients build practical evaluation workflows that connect formulation properties with biological readouts, enabling clearer selection of spleen-oriented LNP candidates.
Spleen-targeted LNP delivery can be achieved by tuning both organ-level biodistribution and immune-cell interaction. Passive spleen targeting is often influenced by particle size, PEG-lipid structure, surface charge, ionizable lipid chemistry, and helper lipid composition, which can shift LNP distribution away from dominant liver uptake and toward splenic accumulation. Recent studies also show that selective organ targeting strategies, long-chain PEGylated lipids at low molar ratios, and specific ionizable lipid structures can enhance spleen-oriented mRNA delivery and promote uptake by antigen-presenting cells. Active targeting may further introduce ligands such as mannose, antibodies, peptides, or immune-cell recognition motifs to improve interaction with dendritic cells, macrophages, B cells, or T cells. For development, targeting success should be evaluated by spleen accumulation, cell-specific uptake, payload expression, encapsulation stability, and functional immune-cell response rather than biodistribution alone.
